Algeta and Lumiphore Announce Further Expansion of Their Global Partnership
for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and
RICHMOND, Calif., May 2, 2013
RICHMOND, Calif., May 2, 2013 /PRNewswire/ --Lumiphore, Inc., a biotechnology
leader in new proprietary bi-functional metal-chelation technology for use in
targeted radiopharmaceuticals has announced that Algeta ASA (OSE:ALGETA), a
company focused on the development of novel targeted cancer therapeutics, has
exercised its option to take an exclusive worldwide licence to Lumiphore's
patented Lumi4^® bi-functional chelator technology and has extended the
collaboration to include additional chelator families. These technologies are
currently being developed by Algeta to conjugate thorium-227 to
tumor-targeting molecules to create Targeted Thorium Conjugates (TTCs).
Lumiphore's Lumi4^® technology is based on a unique class of bi-functional
metal chelators^1 that forms a cage structure surrounding and tightly binding
thorium-227, which can then be covalently attached to a range of
tumor-targeting molecules, such as monoclonal antibodies, to create cancer
therapeutics. These bi-functional chelators provide a critical component
enabling payload delivery for radio-therapeutic agents. Algeta originally
signed an option/license agreement with Lumiphore around this technology in
2010 and subsequently extended it to enable further evaluation to be
conducted. This stage of evaluation has now been completed successfully.
In parallel with this license agreement, Algeta has also been granted a
license by Lumiphore covering a second class of bi-functional chelators that
bind strongly to thorium-227, with the option of including a further selection
of compounds within that license, if future exploratory work confirms their
promise. Under the agreements, Algeta has the future potential to develop in
vivo companion diagnostics for radio-imaging.
"Lumiphore's goal is to bring the benefits of bi-functional metal-chelation
technology, through a variety of synthetic designs, to therapeutic markets
that use targeted radiopharmaceuticals to treat cancer by the tumoricidal
action of the radionuclide micro-irradiation. The ability to chelate
radioactive metal isotopes (radiotracers) and covalently attach them to
therapeutic antibodies, peptides, proteins, or other receptor targeting
molecules will benefit targeted delivery to cancer sites and has the potential
to make current therapeutic antibodies more effective," said Dr. Ken Raymond,
President and CEO of Lumiphore. "Our technology also offers another
therapeutic modality for those using antibody-drug conjugates," explained
Steve Blose, Lumiphore's Chief Business Officer. He further explained that
pharmaceutical companies using therapeutic antibodies could incorporate
Lumiphore's technology to develop site-directed in vivo radiodiagnostics to
diagnose and monitor therapeutic efficacy through radio-imaging.
Thomas Ramdahl, Algeta's Chief Technology Officer, said: "Algeta is assembling
a broad portfolio of proprietary technologies (including bi-functional
chelators, linkers and tumor-targeting molecules), intellectual property and
expertise as a platform for generating Target Thorium Conjugates, or TTCs.
The addition of the Lumiphore technologies to the portfolio through this
license and further option agreements will ensure that we have access to the
best bi-functional chelators for thorium-227 as we seek to create a pipeline
of TTCs designed to address multiple high-value opportunities in targeted
About Lumiphore, Inc.
Based in Richmond, California, Lumiphore, Inc., a privately held company, is a
biotechnology leader in the development of proprietary fluorescent-metal
lanthanide and chelation technology for use in high-value imaging and
therapeutic applications which are commercialized through market-specific
alliances with corporate partners. Lumiphore has exclusive licenses to the
basic science developed at the University of California, Berkeley in the
laboratory of Professor Kenneth N. Raymond, a world expert on lanthanide and
actinide chemistry. For more information please visit www.lumiphore.com.
Lumi4® is a registered mark of Lumiphore, Inc.
Algeta is a company focused on developing novel targeted therapies for
patients with cancer based on its alpha-pharmaceutical platform. The Company
is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC,
based in Cambridge, MA performing commercial marketing operations in the US.
Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more
information please visit www.algeta.com.
For Lumiphore, Inc.
Kenneth N. Raymond, Ph.D. Tel./FAX: +510-232-8455
President and Chairman firstname.lastname@example.org
For Algeta ASA
Mike Booth / Renate Birkeli +47 23 00 67 32
Communications & Corporate Affairs email@example.com
Mark Swallow +44 207 638 9571
Citigate Dewe Rogerson firstname.lastname@example.org
Knut Ekern +47 22 04 82 00
Gambit Hill & Knowlton email@example.com
Kari Watson +1 781 235 3060
MacDougall Biomedical Communications firstname.lastname@example.org
^1 Known as aromatic macrocyclic bi-functional chelators (AMBFs): one end
binds the radionuclide/radiotracer (thorium-227) and the other end links to
the tumor-targeting molecule.
SOURCE Lumiphore, Inc.
Press spacebar to pause and continue. Press esc to stop.